Accession Number ADA583376
Title Phosphoramidate-based Peptidomimetic Prostate Cancer PET Imaging Agents.
Publication Date Jul 2013
Media Count 18p
Personal Author S. F. Dannoon
Abstract The main goal is to develop a PET imaging agent based on modifying the peptidomimetic PSMA inhibitor which will result in improved tumor uptake and clearance mechanism. Different fluorination approaches were attempted with PSMA module compounds such as direct labeling, cupper free chemistry and the use of prosthetic group (SFB). The direct labeling approach has been eliminated as an option due to the instability of the fluorination. As for the cupper free chemistry labeling approach, the final purification step is in progress to provide a final product with higher specific activity (less mass for better imaging). In addition, the production of SFB has been attempted for labeling the module compounds as well and the work is ongoing. Once the labeling approaches are established, and then the labeling of the modified PSMA inhibitor analogues will be investigated in vitro as well as in vivo.
Keywords Antigens
Chemistry
Click chemistry
Diagnosis(Medicine)
Fluorination
Fluorine-18
In vitro analysis
In vivo analysis
Inhibitors
Modular construction
Neoplasms
Peptidomimetic
Prostate cancer
Prosthetics
Psma(Prostate specific membrane antigen)
Purification


 
Source Agency Non Paid ADAS
NTIS Subject Category 57E - Clinical Medicine
Corporate Author California Univ., San Francisco.
Document Type Technical report
Title Note Annual summary rept. 20 Jun 2012-19 Jun 2013.
NTIS Issue Number 1401
Contract Number W81XWH-11-1-0464

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader